Evidence map›Paper›PMID 37161446›Full record

ArticleTurkish journal of pharmaceutical sciences2023

Radiolabeling, Quality Control, and Cell Binding Studies of New

Meliha Ekinci, Derya İlem Özdemir, Emre Özgenç, Evren Gündoğdu, Makbule Aşıkoğlu

Open access · diamondAbstract read
In one paragraph

Article in Turkish journal of pharmaceutical sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 92% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Meliha EkinciEge University, Faculty of Pharmacy, Department of Radiopharmacy, İzmir, Türkiye.ORCID 0000-0003-1319-3756
Derya İlem ÖzdemirEge University, Faculty of Pharmacy, Department of Radiopharmacy, İzmir, Türkiye.ORCID 0000-0002-1062-498X
Emre ÖzgençEge University, Faculty of Pharmacy, Department of Radiopharmacy, İzmir, Türkiye.ORCID 0000-0002-7586-8520
Evren GündoğduEge University, Faculty of Pharmacy, Department of Radiopharmacy, İzmir, Türkiye.ORCID 0000-0003-2111-101X
Makbule AşıkoğluEge University, Faculty of Pharmacy, Department of Radiopharmacy, İzmir, Türkiye.ORCID 0000-0002-4095-2714
Ege University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Early detection of bone cancer is critical for treating symptoms, minimizing pain, and increasing overall quality of life. It is critical to develop novel radiopharmaceuticals with high labeling efficiency and stability for the diagnosis of bone cancer. This research aims to design a novel radiopharmaceutical that may be used to diagnose bone cancer. Materials and Methods: In this study, ibandronate sodium (IBD), a bisphosphonate analog, was radiolabeled with technetium-99m [ Results: According to the results obtained, optimal radiolabeling procedure was obtained for [ Conclusion: The newly produced radiopharmaceutical is very promising according to the results of

Indexed as

bone cancer cellsIbandronate sodiumradiolabelingradiopharmaceuticalstechnetium-99m

Identifiers

PMID37161446
PMCPMC10176626
OpenAlexW4281650287

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.